3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
3
Melanoma
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Interventions
pembrolizumab
3
napabucasin
3
Bevacizumab
3
entinostat
2
Paclitaxel
2
Ocoxin
2
Leucovorin
2
Irinotecan
2
Immunotherapy
2
Gemcitabine
2
Fluorouracil
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vorasidenib
1
sipuleucel-T
1
pralsetinib
1
palbociclib
1
luprolide acetate gel depot
1
linifanib
1
lenvatinib
1
interferon gamma-1b
1
ficlatuzumab
1
durvalumab
1
catumaxomab
1
Vaccines
1
VB6-845 fusion protein
1
Taxes
1
Sorafenib
1
Pemetrexed
1
Papillomavirus Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Glandular and Epithelial
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled